Atezolizumab plus tivozanib for immunologically cold tumor types: the IMMCO-1 trial.
Brian H Ramnaraign, Ji-Hyun Lee, Azka Ali...
https://pubmed.ncbi.nlm.nih.gov/36399037/Actively Recruiting
Led by University of Florida · Updated on 2026-07-13
29
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating the combination of the immune checkpoint inhibitor atezolizumab and the VEGF tyrosine kinase inhibitor tivozanib to treat several immunologically cold cancers that generally respond poorly to immunotherapy alone. These cancers include prostate cancer, biliary tract cancers, soft tissue sarcomas, neuroendocrine tumors, colorectal cancer, pancreatic cancer, and certain breast cancers. The study aims to determine whether blocking VEGF can improve immune response in these tumors. Participants receive atezolizumab intravenously at a dose of 1680 mg on Day 1 of each 28-day cycle. They also take oral tivozanib daily for 21 days within each 28-day cycle. During the early phase of the study, participants receive either 1.34 mg or 0.89 mg of tivozanib per day, while in the later phase, all receive 0.89 mg daily. The study includes both phase 1B dose-finding and phase 2 evaluation stages. Participants are closely monitored through imaging and other assessments to measure tumor response, progression-free survival, overall survival, and disease control rate over 30 months. Eligibility requires advanced cancers with prior treatments or no standard options, adequate organ function, and other health criteria. The study excludes those with certain immune conditions, prior VEGF inhibitor treatments, or unstable medical issues. The participation period extends until study completion in mid-2027, with ongoing safety and efficacy evaluations.
CONDITIONS
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
C
Chloe Quintero
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Florida
Lead Sponsor
Genentech, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational Combination Therapy | Standard Treatment Options (per guidelines) |
|---|---|---|
| What is it? | Atezolizumab plus tivozanib is a combination of an immune checkpoint inhibitor and a VEGFR tyrosine kinase inhibitor, given to participants with advanced or metastatic immunologically cold cancers in a single-arm clinical trial. | Current clinical guidelines recommend various standard therapies, supportive care, or clinician-selected regimens for advanced, unresectable, or metastatic solid tumors that have progressed after standard treatments. These include regimens tailored to the specific tumor type and prior therapies. |
| Role in trial | All enrolled subjects receive atezolizumab plus tivozanib. The combination is evaluated for response rates, progression-free survival, and disease control. | The external comparator represents typical clinical management options according to guidelines for patients who have exhausted or are intolerant to standard therapy. No investigational intervention is used. |
| Primary use | To assess the effectiveness and safety of the investigational combination as treatment for advanced or metastatic immunologically cold cancers. | Guidelines recommend using available therapies or best supportive care for patients with advanced disease when standard lines have failed, aiming to manage symptoms and improve or maintain quality of life. |
| How is it given? | Atezolizumab is given intravenously every 28 days. Tivozanib is taken orally daily for 21 days of each 28-day cycle. Dose escalation (1.34 mg or 0.89 mg tivozanib) was evaluated during phase 1B. Phase 2 participants receive 0.89 mg/day. | Guidelines recommend selection of appropriate therapy based on disease subtype, prior therapy, and patient factors. Administration depends on the specific regimen chosen, with supportive care as an option. No mandatory investigational drug combination is given. |
| Evidence status | Early-phase clinical evidence is available from the IMMCO-1 trial; full efficacy and long-term outcomes have not yet been established in larger trials. | Multiple guideline-recommended regimens and best supportive care for advanced solid tumors have established roles with published evidence from clinical trials and consensus guidelines. |
| Important limitations | Results reflect early-phase, single-arm clinical data; lack of randomized control limits interpretation. Different tumor types and prior treatments may affect outcomes. Larger studies are needed to confirm efficacy and safety. | Standard treatments may offer limited benefit for immunologically cold, advanced cancers after multiple prior therapies. Recommendations are partly based on consensus or expert opinion, and patients may have variable response. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 30 months
Participants receive atezolizumab intravenously once every 28 days and take oral tivozanib daily for 21 days within each 28-day cycle. Dosage varies by study phase.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Brian H Ramnaraign, Ji-Hyun Lee, Azka Ali...
https://pubmed.ncbi.nlm.nih.gov/36399037/University of Florida
Lead Sponsor
Genentech, Inc.
Collaborating Sponsor